Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Injectable Medicines That Help Manage Type 2 Diabetes: Glucagon-Like Peptide-1 Receptor Agonists
AI simplified
Abstract
Since 2005, five new GLP-1 receptor agonists have been approved for treating type 2 diabetes mellitus (T2DM).
- Liraglutide, albiglutide, dulaglutide, and lixisenatide are among the approved medications.
- A once-weekly formulation of exenatide is also available for T2DM treatment.
- Semaglutide is currently under FDA review.
- Exenatide delivered via an osmotic mini-pump is also under consideration.
AI simplified